| Literature DB >> 30683058 |
Abraham Degarege1,2, Merhawi T Gebrezgi3, Consuelo M Beck-Sague4, Mats Wahlgren5, Luiz Carlos de Mattos6, Purnima Madhivanan3,7.
Abstract
BACKGROUND: Malaria clinical outcomes vary by erythrocyte characteristics, including ABO blood group, but the effect of ABO blood group on asymptomatic, uncomplicated and placental Plasmodium falciparum (P. falciparum) infection remains unclear. We explored effects of ABO blood group on asymptomatic, uncomplicated and placental falciparum infection in the published literature.Entities:
Keywords: ABO blood type; Asymptomatic malaria; Placental malaria; Uncomplicated malaria
Mesh:
Substances:
Year: 2019 PMID: 30683058 PMCID: PMC6346527 DOI: 10.1186/s12879-019-3730-z
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1PRISMA flow diagram showing the number of articles retrieved, screened, excluded and included at each stage of the search
Fig. 2Forest plot showing the odds of uncomplicated P. falciparum infection in individuals with blood group A, B, AB or non-O vs those with blood group O
Fig. 3Forest plot showing the odds of asymptomatic P. falciparum infection in individuals with blood group A, B, AB or non-O vs those with blood group O
Fig. 4Forest plot showing the odds of asymptomatic/uncomplicated P. falciparum infection in individuals with blood group A, B, AB or non-O vs those with blood group O
Meta-analysis of the studies that compare the odds of placental P. falciparum infection among individuals with blood group A, B, AB or non-O vs those with blood type O
| Odds of Placental malaria (95% CI) | |||||||
|---|---|---|---|---|---|---|---|
| Parity | Placental malaria Type | Study | Sample size | A vs O | B vs O | AB vs O | Non-O vs O |
| Primiparae or Multiparae | Active or passive vs none | Adam et al. 2007 | 293 | 0.8 (0.44, 1.44) | 0.55 (0.27, 1.1) | 0.57 (0.21, 1.55) | 0.67 (0.41, 1.1) |
| Loscertales & Brabin, 2006 | 198 | 1.35 (0.63, 2.91) | 1.17 (0.59, 2.29) | 1.58 (0.28, 9.01) | 1.26 (0.71, 2.22) | ||
| Senga et al. 2007 | 647 | 1.32 (0.89, 1.96) | 1.22 (0.83, 1.79) | 3.68 (1.39, 9.74) | 1.35 (0.99, 1.85) | ||
| Bedu-Addo et al. 2014 | 827 | 1.16 (0.81, 1.66) | 1.62 (1.09, 2.39) | 1.77 (0.8, 3.91) | 1.38 (1.04, 1.85) | ||
| Adegnika et al. 2011 | 378 | 1.11 (0.39, 3.19) | 2.38 (0.91, 6.23) | 2.00 (0.23, 17.13) | 1.64 (0.75, 3.59) | ||
| Ukaga et al. 2007 | 586 | 0.72 (0.46, 1.13) | 0.68 (0.39, 1.18) | 0.21 (0.07, 0.62) | 0.61 (0.42, 0.89) | ||
| Adam et al. 2009 | 236 | – | – | – | 1.25 (0.91, 2.5) | ||
| Alim et al. 2015 | 126 | – | – | – | 1.11 (0.4, 3.33) | ||
| summary OR (95% CI) | 0.97 (0.75, 1.19) I2 = 8.2%, | 1.02 (0.64, 1.40) I2 = 58.0%, | 0.59 (0.02, 1.14) | 1.01 (0.73, 1.29) I2 = 58.8%, | |||
| Primiparae | Active vs uninfected | Adam et al. 2007 | 293 | 2/31 vs 0/51 | 0/24 vs 0/51 | 1/8 vs 0/51 | 3/50 vs 0/51 |
| Loscertales & Brabin, 2006 | 198 | 0.55 (0.15, 1.99) | 0.33 (0.10, 1.08) | – | 0.41 (0.16, 1.08) | ||
| Senga et al. 2007 | 647 | 0.31 (0.10, 0.97) | 0.79 (0.30, 2.06) | 0.93 (0.06, 15.62) | 0.54 (0.24, 1.21) | ||
| Bedu-Addo et al. 2014 | 827 | 2.59 (1.03, 6.50) | 1.56 (0.84, 2.91) | 4.53 (0.52, 39.74) | 1.90 (1.10, 3.28) | ||
| Adegnika et al. 2011 | 378 | 4.8 (0.73, 31.48) | 1.85 (0.16, 2.2) | - | 3.2 (0.55, 18.56) | ||
| summary OR (95% CI) | 0.41 (0.003, 0.82) I2 = 1.4%, | 1.04 (0.3, 1.78) | 1.42 (−5.81, 8.65) | 0.75 (0.17, 1.34) I2 = 53.8%, | |||
| Passive vs uninfected | Adam et al. 2007 | 293 | 0.46 (0.15, 1.41) | 0.31 (0.08, 1.20) | 0.87 (0.15, 5.00) | 0.44 (0.18, 1.08) | |
| Loscertales & Brabin, 2006 | 198 | 2.13 (0.42, 10.73) | 1.28 (0.28, 5.93) | – | 2.00 (0.55, 7.18) | ||
| Senga et al. 2007 | 647 | 1.28 (0.58, 2.81) | 1.24 (0.54, 2.83) | 2.48 (0.26, 23.38) | 1.32 (0.67, 2.52) | ||
| Bedu-Addo et al. 2014 | 827 | – | – | – | 2.23 (1.17, 4.26) | ||
| summary OR (95% CI) | 0.68 (0.13, 1.22) I2 = 0.0%, | 0.59 (0.03 1.21) I2 = 14.4%, | 0.94 (0.44, 3.31) I2 = 0.0%, | 0.82 (0.08, 1.57) I2 = 42.5%, | |||
| Active vs passive | Loscertales & Brabin, 2006 | 198 | 0.26 (0.05, 1.26) | 0.63 (0.27, 1.49) | 0.38 (0.04, 3.53) | 0.42 (0.2, 0.86) | |
| Senga et al. 2007 | 647 | 0.24 (0.08, 0.70) | 0.69 (0.31, 1.53) | 0.49 (0.05, 4.34) | 0.46 (0.23, 0.92) | ||
| Bedu-Addo et al. 2014 | 827 | – | – | – | 1.44 (0.56, 3.69) | ||
| summary OR (95% CI) | 0.24 (0.03, 0.52), | 0.66 (0.23, 1.09), I2 = 0.0%, | 0.42 (0.01, 1.78), | 0.46 (0.23, 0.69) | |||
| Multiparae | Active vs uninfected | Adam et al. 2007 | 293 | 3.59 (0.66, 19. 69) | 2 (0.26, 15.12) | – | 2.37 (0.47, 11.91) |
| Loscertales & Brabin, 2006 | 198 | 1.55 (0.45, 5.34) | 2.07 (0.72, 5.93) | 2.07 (0.26, 16.27)) | 1.87 (0.77, 4.56) | ||
| Senga et al. 2007 | 647 | 1.78 (0.95, 3.35) | 1.54 (0.84, 2.86) | 5.27 (1.44, 19.32) | 1.78 (1.07, 2.96) | ||
| Bedu-Addo et al. 2014 | 827 | 0.21 (0.11, 0.40) | 0.36 (0.19, 0.66) | 0.36 (0.12, 1.07) | 0.29 (0.17, 0.48) | ||
| Adegnika et al. 2011 | 378 | 0.51 (0.11, 2.37) | 2.59 (0.91, 7.37) | 2.44 (0.27, 21.98) | 1.36 (0.55, 3.34) | ||
| summary OR (95% CI) | 0.76 (0.02, 1.54) I2 = 51.7%, | 1.11 (0.15, 2.07) I2 = 52.2%, | 0.38 (0.09, 0.86) I2 = 0.0%, | 1.20 (0.22, 2.19) I2 = 72.1%, | |||
| Passive vs uninfected | Adam et al. 2007 | 293 | 0.56 (0.19, 1.66) | 0.99 (0.37, 2.62) | 0.47 (0.10, 1.94) | 0.70 (0.32, 1.53) | |
| Loscertales & Brabin, 2006 | 198 | 3.22 (0.94, 11.05) | 2.93 (0.94, 9.13) | – | 2.76 (1.04, 7.34) | ||
| Senga et al. 2007 | 647 | 1.22 (0.58, 2.58) | 1.18 (0.58, 2.39) | 6.32 (1.71, 23.41) | 1.38 (0.78, 2.45) | ||
| summary OR (95% CI) | 0.82 (0.24, 1.41) I2 = 0.0%, | 1.16 (0.46, 1.85) I2 = 0.0%, | 1.01 (0.001, 2.77) | 1.06 (0.38, 1.74) I2 = 31.8%, | |||
| Active vs passive | Loscertales & Brabin, 2006 | 198 | 1.46 (0.6, 3.54) | 0.71 (0.21, 2.34) |
| 0.68 (0.24, 1.95) | |
| Senga et al. 2007 | 647 | 1.46 (0.6, 3.54) | 1.31 (0.56, 3.08) |
| 1.29 (0.64, 2.59) | ||
| Adam et al. 2007 | 293 | 5.18 (0.76, 21.87) | 2.9 (0.36, 26.39) |
| 1.21 (0.16, 9.23) | ||
| summary OR (95% CI) | 1.49 (0.46, 2.53) I2 = 0.0%, | 0.97 (0.16, 1.78) I2 = 0.0%, | – | 0.95 (0.31, 1.59) I2 = 0.0%, | |||
Summary OR estimated using a meta-analysis technique applying fixed (I2 < 30%) or random (I2 ≥ 30%) effect model. Statistical significance of the heterogeneity of the studies was tested using the Cochran’s Q test at α = 5%
Assessment of the quality of all studies included in the review
| Study no. | Author, Year [References] | Selection bias | Study design | Confounders | Blinding | Data collection methods | Withdrawals and drop-outs | Final rating |
|---|---|---|---|---|---|---|---|---|
| 1 | Adam et al. 2009 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 2 | Adam et al. 2007 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 3 | Adegnika et al. 2011 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 4 | Alemu and Mama, 2016 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 5 | AlIi et al. 2010 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 6 | Alim et al. 2015 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 7 | Amodu et al. 2012 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 8 | Bedu-Addo et al. 2014 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 9 | Boel et al. 2012 [ | 1 | 1 | 2 | 2 | 1 | 2 | 1 |
| 10 | Carvalho et al. 2010 [ | 1 | 2 | 2 | 2 | 1 | 2 | 1 |
| 11 | Cavasini et al. 2006 [ | 1 | 2 | 2 | 2 | 1 | 2 | 1 |
| 12 | Degarege et al. 2012 [ | 2 | 3 | 1 | 1 | 2 | 2 | 1 |
| 13 | Fowkes et al. 2008 [ | 2 | 3 | 3 | 2 | 2 | NA | 3 |
| 14 | Giha et al. 2000 [ | 2 | 1 | 3 | 2 | 1 | 2 | 2 |
| 15 | Gupte et al. 2012 [ | 2 | 2 | 3 | 2 | 2 | 2 | 2 |
| 16 | Igbeneghu et al. 2012 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 17 | Jeremiah et al. 2012 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 18 | Joshi et al. 1987 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 19 | Kaisar et al. 2013 [ | 1 | 3 | 2 | 2 | 1 | NA | 2 |
| 20 | Kassime & Ejezie, 1982 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 21 | Loscertales & Brabin, 2006 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 22 | Lwanira et al. 2015 [ | 1 | 1 | 1 | 2 | 2 | 1 | 1 |
| 23 | Migot-Nabias et al. 2000 [ | 2 | 1 | 1 | 2 | 1 | 2 | 1 |
| 24 | Migot-Nabias et al. 2006 [ | 2 | 1 | 1 | 2 | 1 | 2 | 1 |
| 25 | Missinou et al. 2003 [ | 2 | 1 | 2 | 2 | 1 | 2 | 1 |
| 26 | Nwauche et al. 2011 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 27 | Ojurongbe et al. 2011 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 28 | Panda et al. 2012 [ | 2 | 3 | 2 | 2 | 1 | NA | 2 |
| 29 | Panda et al. 2011 [ | 2 | 3 | 2 | 2 | 1 | NA | 2 |
| 30 | Pant et al. 1992a [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 31 | Pant et al. 1992b [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 32 | Pant et al. 1997 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 33 | Pathirana et al. 2004 [ | 2 | 3 | 3 | 1 | 1 | NA | 3 |
| 34 | Rabha et al. 2012 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 35 | Senga et al. 2007 [ | 2 | 3 | 3 | 2 | 2 | NA | 3 |
| 36 | Singh et al. 1995 [ | 2 | 1 | 2 | 2 | 1 | 2 | 1 |
| 37 | Tadesse & Tadesse, 2013 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 38 | Tekeste & Petros, 2010 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 39 | Thakur & Verma, 1992 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 40 | Ukaga et al. 2007 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 41 | Uneke et al. 2006 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
| 42 | Zerihun et al. 2011 [ | 2 | 3 | 3 | 2 | 1 | NA | 3 |
1 = strong; 2 = moderate; 3 = weak; NA = not applicable